Dual-time 18 F-FDG PET/CT for the detection of liver metastases in breast cancer

Alessio Annovazzi, Sandra Rea, Patrizia Vici, Alessandra Fabi, Rosa Sciuto

Research output: Contribution to journalArticle

Abstract

Objective The aim was to investigate the diagnostic potential of dual-time-point 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT) in patients with breast cancer with known or suspected liver metastases and to assess its clinical value on clinical management. Patients and methods A total of 151 consecutive patients with breast cancer who underwent 18 F-FDG PET/CT scan for staging or restaging, in whom an additional delayed scan of the liver was performed, were retrospectively evaluated. Results Overall, 18 F-FDG PET/CT showed the presence of 146 liver metastases in 57 patients. Overall, 54 of these lesions were clearly identified at standard whole-body acquisition, 49 were suspected and 43 were missed in early acquisition. Only 59.6% of patients with liver involvement were clearly identified at the first scan. A high percentage of patients (48.3%) showed at least one liver lesion suspected on standard acquisition which was not more confirmed in late scan. Maximum tumour standardized uptake value of liver metastases was significantly higher in delayed as compared with standard acquisition (6.5±2.4 vs. 5.3±1.6; P<0.0001). The higher detection rate in late acquisition altered patient management in a relative low number of cases in the whole series (15.8%) and in a higher proportion (28.6%) in the group of patients with exclusive liver involvement. Conclusion The results of the study revealed the potential usefulness of late liver acquisition in patients with breast cancer with suspected or known liver metastases. Its use should be advocated in case of inconclusive results on standard acquisition to improve the study interpretation confidence or to increase the accuracy in specific clinical settings.

Original languageEnglish
Pages (from-to)1183-1189
Number of pages7
JournalNuclear Medicine Communications
Volume39
Issue number12
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Liver
Fluorodeoxyglucose F18
Neoplasms

Keywords

  • 18 F-fluorodeoxyglucose positron emission tomography/computed tomography
  • breast cancer
  • dual-time-point acquisition
  • liver metastases

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Dual-time 18 F-FDG PET/CT for the detection of liver metastases in breast cancer. / Annovazzi, Alessio; Rea, Sandra; Vici, Patrizia; Fabi, Alessandra; Sciuto, Rosa.

In: Nuclear Medicine Communications, Vol. 39, No. 12, 01.12.2018, p. 1183-1189.

Research output: Contribution to journalArticle

@article{bba3316dd1564ffc94ef46e0f1394395,
title = "Dual-time 18 F-FDG PET/CT for the detection of liver metastases in breast cancer",
abstract = "Objective The aim was to investigate the diagnostic potential of dual-time-point 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT) in patients with breast cancer with known or suspected liver metastases and to assess its clinical value on clinical management. Patients and methods A total of 151 consecutive patients with breast cancer who underwent 18 F-FDG PET/CT scan for staging or restaging, in whom an additional delayed scan of the liver was performed, were retrospectively evaluated. Results Overall, 18 F-FDG PET/CT showed the presence of 146 liver metastases in 57 patients. Overall, 54 of these lesions were clearly identified at standard whole-body acquisition, 49 were suspected and 43 were missed in early acquisition. Only 59.6{\%} of patients with liver involvement were clearly identified at the first scan. A high percentage of patients (48.3{\%}) showed at least one liver lesion suspected on standard acquisition which was not more confirmed in late scan. Maximum tumour standardized uptake value of liver metastases was significantly higher in delayed as compared with standard acquisition (6.5±2.4 vs. 5.3±1.6; P<0.0001). The higher detection rate in late acquisition altered patient management in a relative low number of cases in the whole series (15.8{\%}) and in a higher proportion (28.6{\%}) in the group of patients with exclusive liver involvement. Conclusion The results of the study revealed the potential usefulness of late liver acquisition in patients with breast cancer with suspected or known liver metastases. Its use should be advocated in case of inconclusive results on standard acquisition to improve the study interpretation confidence or to increase the accuracy in specific clinical settings.",
keywords = "18 F-fluorodeoxyglucose positron emission tomography/computed tomography, breast cancer, dual-time-point acquisition, liver metastases",
author = "Alessio Annovazzi and Sandra Rea and Patrizia Vici and Alessandra Fabi and Rosa Sciuto",
year = "2018",
month = "12",
day = "1",
doi = "10.1097/MNM.0000000000000918",
language = "English",
volume = "39",
pages = "1183--1189",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Dual-time 18 F-FDG PET/CT for the detection of liver metastases in breast cancer

AU - Annovazzi, Alessio

AU - Rea, Sandra

AU - Vici, Patrizia

AU - Fabi, Alessandra

AU - Sciuto, Rosa

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Objective The aim was to investigate the diagnostic potential of dual-time-point 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT) in patients with breast cancer with known or suspected liver metastases and to assess its clinical value on clinical management. Patients and methods A total of 151 consecutive patients with breast cancer who underwent 18 F-FDG PET/CT scan for staging or restaging, in whom an additional delayed scan of the liver was performed, were retrospectively evaluated. Results Overall, 18 F-FDG PET/CT showed the presence of 146 liver metastases in 57 patients. Overall, 54 of these lesions were clearly identified at standard whole-body acquisition, 49 were suspected and 43 were missed in early acquisition. Only 59.6% of patients with liver involvement were clearly identified at the first scan. A high percentage of patients (48.3%) showed at least one liver lesion suspected on standard acquisition which was not more confirmed in late scan. Maximum tumour standardized uptake value of liver metastases was significantly higher in delayed as compared with standard acquisition (6.5±2.4 vs. 5.3±1.6; P<0.0001). The higher detection rate in late acquisition altered patient management in a relative low number of cases in the whole series (15.8%) and in a higher proportion (28.6%) in the group of patients with exclusive liver involvement. Conclusion The results of the study revealed the potential usefulness of late liver acquisition in patients with breast cancer with suspected or known liver metastases. Its use should be advocated in case of inconclusive results on standard acquisition to improve the study interpretation confidence or to increase the accuracy in specific clinical settings.

AB - Objective The aim was to investigate the diagnostic potential of dual-time-point 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT) in patients with breast cancer with known or suspected liver metastases and to assess its clinical value on clinical management. Patients and methods A total of 151 consecutive patients with breast cancer who underwent 18 F-FDG PET/CT scan for staging or restaging, in whom an additional delayed scan of the liver was performed, were retrospectively evaluated. Results Overall, 18 F-FDG PET/CT showed the presence of 146 liver metastases in 57 patients. Overall, 54 of these lesions were clearly identified at standard whole-body acquisition, 49 were suspected and 43 were missed in early acquisition. Only 59.6% of patients with liver involvement were clearly identified at the first scan. A high percentage of patients (48.3%) showed at least one liver lesion suspected on standard acquisition which was not more confirmed in late scan. Maximum tumour standardized uptake value of liver metastases was significantly higher in delayed as compared with standard acquisition (6.5±2.4 vs. 5.3±1.6; P<0.0001). The higher detection rate in late acquisition altered patient management in a relative low number of cases in the whole series (15.8%) and in a higher proportion (28.6%) in the group of patients with exclusive liver involvement. Conclusion The results of the study revealed the potential usefulness of late liver acquisition in patients with breast cancer with suspected or known liver metastases. Its use should be advocated in case of inconclusive results on standard acquisition to improve the study interpretation confidence or to increase the accuracy in specific clinical settings.

KW - 18 F-fluorodeoxyglucose positron emission tomography/computed tomography

KW - breast cancer

KW - dual-time-point acquisition

KW - liver metastases

UR - http://www.scopus.com/inward/record.url?scp=85056511133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056511133&partnerID=8YFLogxK

U2 - 10.1097/MNM.0000000000000918

DO - 10.1097/MNM.0000000000000918

M3 - Article

C2 - 30216230

AN - SCOPUS:85056511133

VL - 39

SP - 1183

EP - 1189

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 12

ER -